Breast Cancer

Breast cancer incidence in women aged 25 to 39 has been steadily increasing for the last 80 years, though researchers indicated that this increase cannot be attributed to changes in parity over time.

This study found significant increases in the first year, which eventually decreased in following years, regarding sickness absence and disability pensions days after a 2010 breast cancer diagnosis.

This study suggested that PV prevalence among postmenopausal women may be high enough to warrant testing even in the absence of early diagnosis age or family history.

This study assessed whether the accumulative, static, or dynamic method was best suited for determining the familial risk of breast cancer.

Tracking large numbers of individualized tumor mutations in cell-free DNA improved minimal residual disease detection in breast cancer patients, though the sensitivity is driven by the number of mutations available to track.

A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.

A recent study found that young women aged 18-39 diagnosed with breast cancer typically suffer through financial hardships regardless of outstanding life circumstances such as career and insurance coverage.

An artificial intelligence algorithm demonstrated better diagnostic performance in breast cancer detection compared to radiologists, who also saw improved performance when aided by the technology.

In this study, researchers found that 59% of the participants reported at least 1 barrier to endocrine therapy adherence, though over half reported that taking endocrine therapy was a joint decision between themselves and their doctor.

In this study, higher intakes of dairy milk were correlated with greater risk of breast cancer, when adjusted for soy intake.

The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting.

The FDA accepted a biologics license application for the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.

With February being National Cancer Prevention Month, here are the latest updates in cancer prevention.

Given the uncertainty about the clinical implications of pathogenic or likely pathogenic variants in moderate penetrance genes and variants of uncertain significance, the findings may underscore the need for targeted genetic counseling education, specifically among young minority women.

ONCOLOGY sat down with Patrick I. Borgen, MD, to discuss the latest trends in surgical and medical oncology, the transformation of breast cancer treatment over the course of his career, and the role he played within that evolution.

In observing individuals aged 65 and older suffering from a recent nonmetastatic cancer, researchers indicated that there is a need to change attitudes toward aging and older people.

A recent study found that patients with stage III breast cancer did not benefit from high-dose chemotherapy, nor did it impact long-term risks of major cardiovascular events.

A recent study suggests older women with estrogen receptor-positive, clinically node-negative, early-stage breast cancer can omit axillary surgery, while nodal positivity declines with advancing age.

A recent study showed survivors aged 60 and older of newly diagnosed nonmetastatic breast cancer reported lower levels of overall well-being and higher levels of symptom burden because of cancer and its treatment.

This suggestion is based on statistically significant distinctions observed in survival rates of patients with single hormone receptor-positive breast cancer vs double hormone receptor-positive/double hormone receptor-negative breast cancer.

Researchers noted that these findings do not indicate that insurance alone will eliminate racial and ethnic disparities in breast cancer; however, it is one systemic change that may ameliorate consistent disparities.

Researchers have yet to determine the optimal use of the AI system, though assessments in the clinical setting indicated that the technology could enhance screening results, potentially identifying breast cancer earlier than the standard of care.

The device allows plastic surgeons and other supervised specialists to ensure consistently superior, realistic, and customizable results for nipple-areola complex tattooing.

These data indicate the need for surveillance and opportunities for intervention in this population.

These results highlight the increased prevalence of cardiovascular risk factors in these patients, and the need for personalized risk assessments for cardiac complications following cardiotoxic therapies.

This data could present a non-invasive option for characterizing tumor heterogeneity to improve personalized prognosis and treatment of patients with breast cancer.

This study provides data for consideration when discussing with patients the use of dietary supplements while undergoing chemotherapy.

Opportunities to further eradicate opioid use as a complication of cancer care should continue to be explored regardless of the data presented according to researchers.

Following breast cancer diagnosis, non-breast cancer causes of death represented a significant number of deaths in this population, providing crucial understanding on how survivors should be counseled on future health risks.

The breakthrough therapy designation was filed for the use of leronlimab as an adjuvant therapy for patients with metastatic triple-negative breast cancer.